World's Best Scientists 2026 revealed!
Dani P. Bolognesi

Dani P. Bolognesi

D-Index & Metrics

Immunology

D-Index
80
Citations
26991
World Ranking
1612
National Ranking
804

Medicine

D-Index
80
Citations
27085
World Ranking
16998
National Ranking
8525

Overview

Dani P. Bolognesi is affiliated with Duke University in the United States. Their research centers on molecular biology, genetics, and medicine, with particular attention to cancer research and biotechnology.

The scientist's recent publication record includes four papers spanning from 2021 to 2023. These papers appear in notable journals and cover topics related to glioma diagnosis and treatment as well as cancer immunotherapy. The titles and publication details are:

  • Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy, 2021, Nature Communications
  • Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial, 2023, The Lancet Child & Adolescent Health
  • 48th Annual Meeting of the International Society for Pediatric Neurosurgery, 2022, Child s Nervous System
  • CTIM-15. RESULTS OF A PHASE IB TRIAL OF RECOMBINANT POLIO:RHINOVIRUS IMMUNOTHERAPY FOR RECURRENT PEDIATRIC HIGH GRADE GLIOMA, 2022, Neuro-Oncology

Their work primarily situates within the intersection of these main fields of study:

  • Biochemistry, Genetics and Molecular Biology
  • Medicine

More specifically, their research subfields include:

  • Genetics
  • Cancer Research
  • Molecular Biology
  • Oncology
  • Biotechnology

Major topics in their research portfolio include:

  • Glioma Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • MicroRNA in disease regulation
  • Cancer-related molecular mechanisms research
  • RNA Research and Splicing
  • Virus-based gene therapy research
  • RNA Interference and Gene Delivery

Dani P. Bolognesi frequently collaborates with a set of coauthors, who have contributed to multiple works alongside them. These collaborators are:

  • Matthias Gromeier
  • Annick Desjardins
  • Henry S. Friedman
  • Roger E. McLendon
  • David M. Ashley

The common publication venues for Dani P. Bolognesi include:

  • Nature Communications
  • The Lancet Child & Adolescent Health
  • Neuro-Oncology
  • Child s Nervous System

Best Publications

  • 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

    H Mitsuya;K J Weinhold;P A Furman;M H St Clair

  • Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

    P A Furman;J A Fyfe;M H St Clair;K Weinhold

  • POTENT SUPPRESSION OF HIV-1 REPLICATION IN HUMANS BY T-20, A PEPTIDE INHIBITOR OF GP41-MEDIATED VIRUS ENTRY

    J M Kilby;S Hopkins;T M Venetta;B DiMassimo

  • ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX

    Robert Yarchoan;Kent J. Weinhold;H. Kim Lyerly;Edward Gelmann

  • Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein

    K Javaherian;A J Langlois;C McDanal;K L Ross

  • Recurrent glioblastoma treated with recombinant poliovirus

    Annick Desjardins;Matthias Gromeier;James E. Herndon;Nike Beaubier

  • A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

    Carl Wild;Terrence Oas;Charlene McDanal;Dani Bolognesi

  • Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides

    Thomas J. Palker;Michael E. Clark;Alphonse J. Langlois;Thomas J. Matthews

  • Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

    Tom Matthews;Miklos Salgo;Michael Greenberg;Jain Chung

  • Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1

    Kashi Javaherian;Alphonse J. Langlois;Greg J. Larosa;Albert T. Profy

  • Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 in Primary Infection and Long-Term-Nonprogressive Infection

    Alice K. Pilgrim;Giuseppe Pantaleo;Oren J. Cohen;Lisa M. Fink

  • A proposed nomenclature for the virion proteins of oncogenic RNA viruses

    J.T August;Dani P Bolognesi;Erwin Fleissner;Raymond V Gilden

  • Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody

    W G Robey;L O Arthur;T J Matthews;A Langlois

  • Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

    M A Skinner;A J Langlois;C B McDanal;J S McDougal

  • Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack

    H K Lyerly;T J Matthews;A J Langlois;D P Bolognesi

  • Evidence for human infection with an HTLV III/LAV-like virus in Central Africa, 1959.

    A.J. Nahmias;J. Weiss;X. Yao;F. Lee

  • Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion

    T J Matthews;K J Weinhold;H K Lyerly;A J Langlois

  • Clade B-Based HIV-1 Vaccines Elicit Cross-Clade Cytotoxic T Lymphocyte Reactivities in Uninfected Volunteers

    Guido Ferrari;Will Humphrey;M. Juliana McElrath;Jean–Louis Excler

  • Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.

    T J Matthews;A J Langlois;W G Robey;N T Chang

  • Assembly of type C oncornaviruses: a model.

    DP Bolognesi;RC Montelaro;H Frank;W Schafer

Frequent Co-Authors

Kent J. Weinhold
Kent J. Weinhold Duke University
Peter J. Fischinger
Peter J. Fischinger National Institutes of Health
Robert C. Gallo
Robert C. Gallo University of South Florida
James N. Ihle
James N. Ihle St. Jude Children's Research Hospital
Heinz Schwarz
Heinz Schwarz Max Planck Society
Barton F. Haynes
Barton F. Haynes Duke University
Thomas J. Matthews
Thomas J. Matthews University of Birmingham
Darell D. Bigner
Darell D. Bigner Duke University
Chin Ho Chen
Chin Ho Chen Duke University
John Bartlett
John Bartlett Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their expertise beyond immunology, pursuing advanced nursing degrees can be a valuable option. Many professionals explore pathways such as the fnp to acnp bridge program online, which allows Family Nurse Practitioners to transition into Acute Care Nurse Practitioners through flexible, specialized coursework.

Accelerated programs are also popular for those looking to enter the healthcare field quickly or advance their careers. Students can consider accelerated np programs designed to fast-track their path to becoming Nurse Practitioners. These programs are often tailored for working professionals seeking efficient, high-quality education.

Non-nurses aiming to join the nursing profession may find online accelerated nursing programs for non nurses particularly useful. These programs provide comprehensive training and credentials in an online format, helping to meet the growing demand for qualified nurses.

Salary expectations are also a crucial consideration. Understanding how much do dnp nurses make can help prospective students evaluate the return on investment for doctoral nursing degrees and plan their career trajectory accordingly.

Best Scientists Citing Dani P. Bolognesi

Trending Scientists

Recently Published Articles